Characterization of the p53 response to oncogene-induced senescence.
BACKGROUND
P53 activation can trigger various outcomes, among them reversible growth arrest or cellular senescence. It is a live debate whether these outcomes are influenced by quantitative or qualitative mechanisms. Furthermore, the relative contribution of p53 to Ras-induced senescence is also matter of controversy.


RESULTS
This study compared situations in which different signals drove senescence with increasing levels of p53 activation. The study revealed that the levels of p53 activation do not determine the outcome of the response. This is further confirmed by the clustering of transcriptional patterns into two broad groups: p53-activated or p53-inactivated, i.e., growth and cellular arrest/senescence. Furthermore, while p53-dependent transcription decreases after 24 hrs in the presence of active p53, senescence continues. Maintaining cells in the arrested state for long periods does not switch reversible arrest to cellular senescence. Together, these data suggest that a Ras-dependent, p53-independent, second signal is necessary to induce senescence. This study tested whether PPP1CA (the catalytic subunit of PP1alpha), recently identified as contributing to Ras-induced senescence, might be this second signal. PPP1CA is induced by Ras; its inactivation inhibits Ras-induced senescence, presumably by inhibiting pRb dephosphorylation. Finally, PPP1CA seems to strongly co-localize with pRb only during senescence.


CONCLUSIONS
The levels of p53 activation do not determine the outcome of the response. Rather, p53 activity seems to act as a necessary but not sufficient condition for senescence to arise. Maintaining cells in the arrested state for long periods does not switch reversible arrest to cellular senescence. PPP1CA is induced by Ras; its inactivation inhibits Ras-induced senescence, presumably by inhibiting pRb dephosphorylation. Finally, PPP1CA seems to strongly co-localize with pRb only during senescence, suggesting that PP1alpha activation during senescence may be the second signal contributing to the irreversibility of the senescent phenotype.
Ruiz
Lidia
L
Experimental Therapeutics Programme, Centro Nacional De Investigaciones Oncológicas, Madrid, Spain.
Traskine
Magali
M
Ferrer
Irene
I
Castro
Estrella
E
Leal
Juan F M
JF
Kaufman
Marcelline
M
Carnero
Amancio
A
D000818:Animals; D020134:Catalytic Domain; D049109:Cell Proliferation; D016922:Cellular Senescence; D016158:Genes, p53; D006579:Heterozygote; D016018:Least-Squares Analysis; D051379:Mice; D008822:Mice, Transgenic; D018613:Microscopy, Confocal; D010641:Phenotype; D054645:Protein Phosphatase 1 / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D018631:ras Proteins / Q000378:metabolism
D016159:Tumor Suppressor Protein p53; C517187:PPP1CA protein, human; D054645:Protein Phosphatase 1; D018631:ras Proteins
J Cell Biochem. 2007 Dec 15;102(6):1400-4
17979151
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):388-92
8380637
Science. 2005 Aug 5;309(5736):886-7
16081723
Genes Dev. 2000 Aug 15;14(16):2015-27
10950866
Genes Dev. 2000 Sep 15;14(18):2358-65
10995391
Cell. 2000 Sep 15;102(6):849-62
11030628
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5025-30
11309506
Oncogene. 2002 Mar 7;21(11):1633-40
11896594
Mol Cell Biol. 2002 May;22(10):3497-508
11971980
Cancer Cell. 2002 Aug;2(2):103-12
12204530
Oncogene. 1999 Nov 1;18(45):6145-57
10557106
Mol Cell Biol. 2000 Apr;20(8):2803-8
10733583
Trends Cell Biol. 2000 May;10(5):197-202
10754563
Genes Dev. 2000 Apr 15;14(8):981-93
10783169
EMBO J. 2000 May 15;19(10):2237-46
10811615
Exp Gerontol. 2000 May;35(3):317-29
10832053
Nucleic Acids Res. 2000 Jun 1;28(11):2234-41
10871344
Nature. 2000 Jul 13;406(6792):207-10
10910364
Cell. 1993 Sep 24;74(6):957-67
8402885
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
7568133
Nature. 1996 Aug 29;382(6594):816-8
8752276
Genes Dev. 1996 Oct 1;10(19):2438-51
8843196
J Biol Chem. 1997 Feb 14;272(7):4528-35
9020179
Cell. 1997 Feb 7;88(3):323-31
9039259
Cell. 1997 Mar 7;88(5):593-602
9054499
Curr Biol. 1997 Jun 1;7(6):375-86
9197238
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2834-7
9501176
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6399-402
9600977
Nature. 1998 Sep 10;395(6698):125-6
9744268
Genes Dev. 1998 Oct 1;12(19):3008-19
9765203
Front Biosci. 1998 Dec 1;3:D1209-19
9835651
Mol Pharmacol. 1999 Sep;56(3):515-25
10462539
Clin Cancer Res. 2005 Feb 15;11(4):1380-5
15746036
Nat Genet. 2005 Jul;37(7):718-26
15924142
Leukemia. 2005 Dec;19(12):2347-50
16208412
Cell Cycle. 2005 Dec;4(12):1722-4
16294043
Cell. 2006 Mar 24;124(6):1169-81
16564011
Cell Death Differ. 2006 Jun;13(6):941-50
16601750
Cold Spring Harb Symp Quant Biol. 2005;70:263-73
16869762
Oncogene. 2006 Aug 28;25(38):5233-43
16936742
N Engl J Med. 2006 Sep 7;355(10):1037-46
16957149
Nature. 2006 Sep 14;443(7108):159
16971940
Genes Dev. 2006 Oct 1;20(19):2687-700
17015431
Biochem J. 2006 Dec 1;400(2):303-13
16895524
Cell. 2006 Dec 29;127(7):1323-34
17182091
Cell Cycle. 2007 May 2;6(9):1006-10
17457049
Front Biosci. 2007;12:4483-96
17485390
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):883-91
17544001
Cell Death Differ. 2003 Apr;10(4):431-42
12719720
Cell. 2003 Jun 13;113(6):703-16
12809602
EMBO J. 2004 Mar 10;23(5):1144-54
14976551
J Cell Biochem. 2004 Jun 1;92(3):514-24
15156563
EMBO J. 2004 Sep 15;23(18):3677-88
15343267
Cell. 1990 Aug 24;62(4):671-80
2143698
Carcinogenesis. 2008 Mar;29(3):491-9
18204081